





	INDEX									
Sl No	Description	Page No.								
1	Introduction -	03 - 03								
	i) Experience & Diversity	04 - 04								
2	ii) Product certification process & investigation flow	05 - 05								
	iii) Non-conformity flow diagram	06 - 06								
3	Regulatory status & agency view	07 - 07								
4	Facilities layout	08 - 11								
5	Capability & capacity	12 - 13								
6	Team structure	14 - 14								
7	Communication plan frequency calendar	15 - 15								
8	Communication plan MIS templates	16 - 18								
9	Import procedure- overseas health products	19 - 19								
10	Training & performance management	20 - 22								
11	Strength of our alliance	23 - 23								
12	Other supporting businesses	24 - 26								
13	Contact details	27 - 27								

Confidential Document www.stabicon.com Email: bd@stabicon.com 2

1. Introduction

Stabicon product certification process management strives to improve processes and align the needs of regulatory with Client objectives on quality product distribution channel. This gives transparency to the process making it more efficient.


It Includes review and testing process to validate that the certified products meet certain standards and comply with a stated designed specification/requirement. Product certification process works towards improving efficiency across the various project stakeholders by helping product evaluation and implement best practices.

2. Experience & Diversity - Laboratory Business Segment

	Section —	2 Experience &	<u> Diversity - Laborator</u>	y Business Segmen	<u>t</u>
	Method Development	Method Validation/Verification	Stability Program	Product Certification for WHO & India Market Release	Spurious & Substandard product Investigation
Experience	9 years	9 years	9 years	9 years	5 years
Dosage	Internal X ₁ Parenteral Internal X ₁		Solid, Liquid, Topical, Parenteral (Internal & External Application)	Solid, Liquid, Topical, Parenteral (Internal & External Application)	Solid, Liquid, Topical, Parenteral
Volume	100 - 200 300 - 500		500 - 700	1000 - 1200	250 - 400
Diversity	Pharmaceutical Rx & OTC, Hygiene, Dietary, Compounding, Biological, Medical Device	Pharmaceutical Rx & OTC, Hygiene, Dietary, Compounding, Biological, Medical Device	Pharmaceutical Rx & OTC, Hygiene, Dietary, Compounding, Biological, Medical Device	Pharmaceutical Rx & OTC, Hygiene, Dietary, Compounding, Biological, Medical Device	Dietary , Pharmaceutical Rx & OTC
Category	Chemical, Enzyme, Peptide, Medical Pentide Medical Device		Chemical, Enzyme, Peptide, Medical Device, Natural, Probiotics based products	Chemical, Enzyme, Peptide, Medical Device, Natural, Probiotics based products	Chemical, Enzyme, Peptide based products
Market	America, Europe, Asia, Australia, Africa, Canada, Middle east	America, Europe, Asia, Australia, Africa	America, Europe, Asia, Australia, Africa	America, Europe, Asia, Australia, Africa	Asia

Confidential Document www.stabicon.com 4





Note:

In case of Non Conformity observed Please refer Non Conformity work flow Diagram

Confidential Document <u>www.stabicon.com</u> Email: <u>bd@stabicon.com</u> 5

Product Certification & Investigation Program Non Conformity Flow Diagram For Chromatographic/Spectrometric Investigation FIR Result LEinvestication CAPA Non Conformity preliminary Value Reject B.D & Project LE/OOS HE/NHE Human Analysis request by result observed by QC/QA Reanalysis Mandatory incharge Approval Non Human CAPAH error Conclusion eport Both Result C1, C2 & Need Further investigation From Manufacturing Site Outcome 1,(A=B) Additional AWR/MDR/ Sample Job Order Preliminary Result & Report Result Matching Amendment Reinjected Preliminary Result Outcome -1, C1 ≠ C2 Result C1.C2 Not Matching b/w Two Invalid Result (A &B) Outcome 2,(A ≠ B) Analysis Analyst/Duplicate Result Preparation Outcom В AWR/ Result Sample/Job Proceed Phase-2(i) Result Not Matching Order/MDR Reject Preliminary Result **Preliminary Result** Outcome -2, C1 = C2Amendment Phase-1 If Reinject Sample Result C1 & C2 Plan & Within Stability Matching b/w Two Approval Report in COA Window Analyst/Duplicate Preparation OOS/OOT/S2/ Repeat Analysis Plan Outcome -1 Outcome-1;A=D1=D2 Report All Three result (A +D1+D2)/Average in COA Preliminary Result + Duplicate Analysis (Matching) Phase-2 Only If Phase -1 Not Feasible Outcome -2 Outcome-2; A ≠D1=D2 Job Order/MDR Amendment Additional AWR/ Result Phase-2(ii) Result Not Matching Reject Preliminary Result & (D1+D2)/Average in COA (D1&D Repeat Analysis Duplicate Plan & Preliminary Result But Repeat Sample Approval Preparation/Two Analysis Analysis Within R & D Limit Outcome -3 Outcome-2= A≠D1≠D2 Result Not Matching With QA/QC estigation From Manufacturin Preliminary Result as Well As Repeat Analysis Not Within R & D Routine Process (Report to A,D1,D2) **Manufacturing Site** QA (Decision) **BD & Project** OOS/OOT/S2 **Process Path** Automation/Project/ AWR- Analytical Work Record FIR- First Information Report OOT- Out Of Trends C - Phase (i) Outcome D - Phase (ii) Outcome Lab Error Process S2 - Deviation/Dissolution OOS- Out Of Specification Phase - 1 Process QA (Report B - Repeated Value MDR - Multi Data Reporting QC (Conclusion) COA- Certificate Of Analysis A - Preliminary Value Phase - 2 Process **Confidential Document** www.stabicon.com Email: bd@stabicon.com 6

3. Regulatory Status & Agency view

















- Approved by Health Canada
- Accredited by laboratory Assessment was done by NABL (National Accreditation Board for Testing & Calibration Laboratories) India as per ISO / IEC 17025:2005
- Approved by **WHO**, **Geneva**; under Prequalification Medicine Program Procedure for Assessing the Acceptability, in Principle of QC Laboratory for use by UN agencies; vide **LIF No.: L 1108**
- Registered with USFDA & DSIR
- Audited & approved by CDSCO (India FDA)


4. i)Storage facility - Administration, Quality Assurance & Sample Storage facility




ii) Analytical Lab Facility



iii) Microbiology Lab facility



iv) Analytical research & development facility



5. Capability & Capacity

	Table No 1 - Chemical Test in Number of Batches Table No 2 - Microbiology sample analysis												
	Validation												
	Sterility	y & BET		Assay		Stability and BET	PET						
	Present Capacity	Infrastructure Available for Expansion	Present Capacity	Infrastructure Available for Expansion	Present Capacity	Infrastructure Available for Expansion	Present Capacity	Infrastructure Available for Expansion					
Week	NA	NA	NA	NA	NA	NA	NA	NA					
Month	10	5	20	10	10	5	10	5					
Yearly	120	60	240	120	120	60	120	120					

	Table No 3 - UPLC, HPLC & GC Chromatographic Sample Analysis											
	Routine Ar	nalysis Project	Method Development & Validation Project		Stability <i>I</i>	analysis Segment Project	AR&D Analysis Segment Project					
	Present Capacity	Infrastructure Available for Expansion	Present Capacity	Infrastructure Available for Expansion	Present Capacity	Infrastructure Available for Expansion	Present Capacity	Infrastructure Available for Expansion				
Week	90	144	10	30	12	36	3	4				
Month	300	576	40	120	48	144	12	16				
Yearly	2880	2304	480	480	576	576	144	192				

Confidential Document <u>www.stabicon.com</u> Email: <u>bd@stabicon.com</u> 12

Table No 4 Microbiology Sample Analysis Stability and BET PET **Microbial Limit Test** Assay Infrastructure Infrastructure Available for Infrastructure Present Infrastructure Available for Present Capacity Present Capacity Present Capacity Available for Available for Expansion Expansion Capacity Expansion Expansion 100 50 50 25 60 30 Week NA NA Month 400 200 200 100 240 120 5 10 Yearly 4800 2800 60 120 2400 2400 1200 1440

6. Team Structure

Table -1 Project Key Stake Holders' Team										
Section	Name	Position	Role in project	Email id	Contact number					
		Business Development Officer	Handling new enquiries and Proposing proposal							
m z		Customer Support Cell Executive	Sample receipt and acknowledgement							
Operation Team		Team Leader	One point contact for update on resources, specifications, status of upcoming project and ongoing projects							
0per		Manager-Project	In charge of techno commercial matters							
		Manager-Quality Assurance	Study report, Investigation							
		Senior Executive- Accounts	Invoicing, Proforma invoice, Remittance							
Теат		Assistant General Manager	Techno-Commercial: Project							
Escalation Team		Senior Manager- Finance	Team Attitude -Administrator & Finance							
Escal		Managing Director	Unethical Issues							

7. Communication plan - frequency calendar

From	Task	Frequency Schedule	MIS Templates
Stabicon	Business development - Summary proposal status	15 days	Refer Table No -1
Stabicon	Post quote prerequisite summary for project execution	15 days	Refer Table No -2
Stabicon	Order book summary for invoicing	30 days	Refer Table No -3
Stabicon	Ongoing project status	15 days	Refer Table No -4
Client	Project forecast	30 days	Refer Table No -5
Stabicon	Non conformity	15 days	Refer Table No -6
Stabicon	Escalation operation review -skype/Telecom	90 days	Refer Table No -7

Communication plan - MIS Templates

Table -1 Business Development - (Month) 2019 for (Client)											
Contact Person	Enquiry date	Feasibility	Quote submitted date	PO date PO number		Date of execution					

	Table -2 Post Quote Prerequisite summary for Project Execution													
Quote Number	Name of the Project	Type of Quote	Study Plan Document (Yes/NO)	Method Transfer (Yes/NO)	Placebo provided by Client (Yes/NO)	Standard to be provided from Stabicon/Client	Impurity to be provided from Stabicon/Client	Sample Estimate Date	Tracking Details					

Table -3 Order Book Summary For Invoicing-(Month) 2019 for (Client)										
Project type	PO number	PO value	Invoiced details	Balance/Open order						


	Table -4 Project Report - (Month) 2019 for (Client)												
PO number	Name of project	No. of batches registered	Resources available	Resources to be procured (from vendor)	Resources to be arranged (from Client)	Analysis start date	Analysis completion date	COA release date					

	Table -5 Project Forecast (Month) 2019 for (Client)												
Plan	Project Name	Project Type	Status	Assignee From Client	Start Date From Client	End Date By Stabicon	Duration In Days	Comments					

Table - 6 Nonconformity-(Month) 2019 for (Client)											
Name of project	Batch number	AR Number	Non conformity type	Test parameter	Investigation report number	Next action	Conclusion				

Table - 7 Escalation Team Review - (Month) 2019 for (Client)								
Grievance for	Action Plan	Issue (Technical /Commercial)	Support by Support by Stabicon Client		Skype date & Participants	Skype/Telecon Agenda	Next scheduled date for Skype/Telecon	

8. Import Procedure - Overseas Health Samples



9.Training & Performance Management


Section 1: Auto Team Training Program

Training SOP for Each Level																				
Level	QC			QA																
					Issuance Monitoring		Distributio	AR & D	FR & D	IT	Automation	Invitro	HR	Finance	Account	Purchas	Project	CSC		
	RS	SS	DY	Microbiolog 5	AVR	Doc(00S/00T/S0 P)	Audit	GLP	n n									e		
Manager	145	86	90	125	95	15	07	11	72	148	110	30	90	105	15	25	12	12	85	70
Asst Manager	135	69	71	101	71	09	04	08	60	132	96	25	74	83	10	17	07	08	70	64
Sr. Team Leader	122	48	57	87	62	05	02	05	55	122	80	20	57	70	07	10	04	04	63	57

Section 2: Competency in Stabicon

Competency in Stabicon								
SL. No	Department	Current Position	Name	No of year & specialization		Current User		
02.110	Department	unitent i canon	, Table	Stabicon and Other	Stabicon	HPLC	Non-HPLC	
1		Manager		20 years experiences in the area of Quality Control and Analytical R&D in Drugs and pharmaceutical industry. Chemical, Instrumental testing in drugs & pharmaceutical and R&D, ISO / IEC 17025:2005, ISO 9001 WHO, and MHRA	01 year 04 months	Yes		
2	Quality Control	Asst. Manager		12 years experiences in the area of Quality Control in Pharmaceutical Industry.	04 years 06 months	Yes		
5		Team Leader		05.5 years experiences in the area of Quality Control in Pharmaceutical Industry.	02 year 00 months	Yes		
6		Executive		3 years experiences in the area of Quality Control in Pharmaceutical Industry.	03 years 02 Months	Yes		
10		Senior Officer		3 years experiences in R&D and Quality control in Pharmaceutical Industry	01 year 03 months	Yes		
15	Research Associate			10 months experiences in the area of Quality Control in Pharmaceutical Industry.	10 Months	Yes		
23		Officer		2.5 years experiences in the area of Quality Control in Pharmaceutical Industry.	10 Months	Yes		
29		Trainee		Fresher	Fresher		Yes	

Section -3 Projects – Department KRA – KPI



Note: Data for example only

10. Strength for our Alliance

- All process mapped & automated.
- All project process & training can be viewed online on each application software complete transparency, traceable & easily accessible to various stakeholders globally.
- Complete transparency, traceable & easily accessible to various stakeholders globally.
- Centralized center for stability & method validation.
- Lean Management, Flexible to adapt for new technology & System.
- Synchronize operation as per global time zone.

11. Other Related Businesses:

Turnkey & Training Portfolio:


We provide concept-to-completion design laboratory for pharmaceutical industry. Our experts will understand your business, possess experience implementing best practices, and will leverage that expertise to enhance your lab's and R&D efficiency. Whether it's for research or routine testing, we can recommend and provide the right solution to address laboratory and development process challenges, helping you drive decisions, maximize resources, and increase productivity.

Sl No	Capabilities				
1	Needs Assessment				
2	Process improvement				
3	3 Complete automation of process				
4	4 Plan and setting up operation centre				
5	Multicentre integration process				
6	Training programs Onsite & offsite Program				
7	Expert Laboratory Personnel training				

Referral Lab:

Poor medicine quality can sometimes lead to serious health consequence & death. Imported or Locally Manufactured Medicines without proper pre & post inspection may be rendered substandard at any point along the medical supply chain, from the point of manufacture through the point of distribution. Substandard medicines undermine governments' investments in health delivery systems. Regulatory body/ Organization Partnering with Stabicon support assist to can address the above challenges by following approaches

Effective Quality Check Points For Medicine



For any queries /discussions, please contact us:

Business Develoment Team

Email: bd@stabicon.com

Contact No: +91 7022281068 ,+ 91 80 41250324

Stabicon Life Sciences Pvt. Ltd.

Corporate Office: 4M-413 l 1st Floor l 3rd block H R B R layout l Kalyan Nagar l Kammanahalli Main Road l

Bengaluru - 560043 l Karnataka India.

Contact No: +91 80 41250324 l R&D Centre: +91 80 27839259/ 9260 l

Website: www.stabicon.com









